ASHKELON, Israel, Dec. 10, 2015 /PRNewswire/ -- Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes or at risk of developing diabetes, announced today that it has hired Boudewijn Baks as International Sales and Business Development Manager for its non-invasive glucose measuring device, GlucoTrack®.
Mr. Baks brings 25 years of National and International sales experience in the Pharmaceutical, Medical Device and Healthcare industries. Most recently he was General Manager (General Commercial Manager SMBG business) of ARKRAY Europe, a leading Japanese Medical Device diagnostics company (from 2011 to 2015). Before that Mr. Baks worked at Abbott Diabetes Care (National Sales Manager Diabetes Care, from 2007 to 2011), Pfizer (sales group manager Endocrinology, from 2000 to 2007), Ferring (business unit manager Urology, from 1993 to 2000), and Merck (sales representative, from 1990 to 1993).
"We are very pleased to announce and welcome Boudewijn as our International Sales and Business Development Manager," said Ron Roobroeck, Director of International Marketing and Sales for GlucoTrack®. "He will be instrumental in expanding our International Marketing and Sales team, as we intend to increase sales of GlucoTrack®. His unique experience will help accelerate our efforts to increase the number of distributors and to manage the local business development managers in their task to support the local distribution of our product."
"I'm excited to join Integrity Applications as the International Sales and Business Development Manager for GlucoTrack®," said Boudewijn Baks. "I consider this not only a next step in my personal career but also an important next step for pre-diabetic and type 2 diabetic patients. People with diabetes deserve new innovative glucose measuring methods. I'm absolutely convinced that Integrity Applications' GlucoTrack® will significantly improve the quality of life of diabetic patients. Together with the rest of our growing marketing and sales team, we will work to bring this non-invasive glucose measuring device to the next level of success. Traditional glucose measuring is the past. Innovative, non-invasive glucose measuring is the future."
GlucoTrack® is a non-invasive device for measuring glucose levels of people with Type 2 diabetes or at risk of developing diabetes that does not require pricking of the fingers to draw blood for daily glucose monitoring. GlucoTrack® features a small sensor that clips to the earlobe and measures the wearer's glucose level by taking measurements using three technologies. The measured signals are analyzed using a proprietary algorithm and displayed on a small handheld device, the size of a mobile phone. The derived glucose measurement is also announced verbally, facilitating use by elderly and vision-impaired diabetes patients.
The GlucoTrack® Model DF-F is expected to begin clinical trials for United States FDA approval in early 2016, subject to approval of Integrity Applications' clinical trials protocol by the FDA.
GlucoTrack® Model DF-F obtained a CE Mark approval in Europe (June 2013) and final CE Mark approval in March 2014 and recently received approval to market the device also to pre-diabetics.
GlucoTrack® Model DF-F is currently under assessment with the China Food and Drug Administration (CFDA) as well as food and drug governing bodies in Japan, South Korea Canada and Australia.
About Integrity Applications, Inc.
Integrity Applications, Inc. is a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Integrity Applications has developed the GlucoTrack® model DF-F non-invasive glucose monitoring device, which is designed to help people with diabetes obtain glucose level measurements without the pain, inconvenience, incremental cost and difficulty or discomfort of conventional (invasive) spot finger stick devices. Integrity Applications operates primarily through its wholly-owned Israeli subsidiary, A.D. Integrity Applications, Ltd. For more information, please visit www.integrity-app.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "expect" and "will" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications' actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications' results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to obtaining regulatory approval in the United States and in foreign jurisdictions; risks relating to the conduct of clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications' filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2014.
CFO Integrity Applications, +972 (8) 675-7878, firstname.lastname@example.org
SOURCE Integrity Applications, Inc.